The brand falls in the gastroenterology segment ... including the final approval to market Mesalamine Delayed- Release Tablets USP, 1.2 g in the US.On 5 July 2017, Cadila Healthcare announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback